AUS
NZ
UK
CA
USA
IND
United Kingdomâs Healthcare Industry
The United Kingdom is one of the worldâs leading nations in marketing and manufacturing of clinical pharmaceuticals and products. The worldâs top 20 pharmaceutical companies have their presence in the UK, apart from this, there are more than 5,600 life science companies actively working in Britain.
In the year 2019, the total turnover of the UK Healthcare industry was over £70 billion out of which £30 billion turnover was through export only, a clear sign of booming international supply-demand of British life science services and goods. Not only medicine and services, but the nation is also one of the most prominent leaders in terms of healthcare publishing as well. It has the highest per capita share of the leading 1 per cent highest cited global life sciences publications.
Historically, the UK has been one of the best countries in term of the most significant biomedical inventions of recent decades, such as the development of IVF in the 1970s. The UK was the country which provided routine universal anticancer vaccine in the year 2008 and offered to young girls to provide safety against carcinogenic strains of HPV. Currently, the nation is showing best capability in the emerging market, for example, artificial intelligence (âAIâ) and digital health with five new AI Medical Centres, which is about to open at nationalised healthcare system (âNHSâ) hospitals in the year 2020.
The UKâs NHS, a government-sponsored universal healthcare system, is treating a million of patients in every 36 hours. The organisation is fully committed to researching and partnership with private industry. The UKâs Government has received £86 million in funding in the Life Sciences Sector and to boost the work and new developments at NHS. Led by the funding, the National Institute for Health and Care Excellence (NICE) and Accelerated Access Collaborative (AAC) simplified the existing path to market for their products and life sciences investors.
The United Kingdom has been supporting investment in the sector and provides Research & development tax breaks. For small and medium-sized enterprises (SMEs), tax relief on allowable Research & Development is 230 per cent, and for large businesses, a taxable credit of 12 per cent is given to qualifying Research & Development expenditure. Among the top ten pharmaceutical companies, the GlaxoSmithKline, the UK based company with a market capitalisation of £92.11 billion, is one of the worldâs fastest expanding pharma company. We will discuss some other major pharma and healthcare companies here which holds a strong potential for the year 2020.
Health Care Stocks To Watch In The Year 2020
NMC Healthcare Plc (LON:NMC)
NMC Health Plc (LON: NMC) is a private services provider of healthcare in the United Arab Emirates. The company is working with an aim to provide the best healthcare facilities for the last 46 years. NMC is the first company from Abu Dhabi, which is listed on London stock exchange.
NMC Healthcare (LON:NMC) â Share Price Performance
At the time of writing, on 20th January 2020 as at 16:35 GMT, the share price of NMC closed at GBX 1,500.0 per share on the London Stock Exchange, a downside of 3.69 per cent or GBX 57.50 per share, versus previous dayâs closing price of GBX 1,557.50 per share.
NMCâs share price of GBX 3,059.0 as on 11th September 2019 was its 52-week peak price, whereas the share price of GBX 1,192.0 as on 20th December 2019 was the 52-week low share price. The current share price was lower by 50.96 per cent from the 52-week high price, whereas it was higher by 25.83 per cent from the 52-week low price. The companyâs market capitalisation was reported at £3.27 billion at the time of writing.
While writing, the beta of the NMC share was at 0.66, which shows low volatility as compared to the benchmark market indexâs movement.
AstraZeneca Plc (LON:AZN)
AstraZeneca Plc (LON:AZN) is a biopharmaceutical company, it is an international science-led business, and its pioneering medicines are used by millions of patients worldwide.
AZN â Share Price Performance
The share price of AZN on 20th January 2020 (as at 16:35 AM GMT), closed at GBX 7,837.0 on the LSE (London Stock Exchange), lower by 0.52 per cent or GBX 41.0 per share, against the last dayâs closing price of GBX 7,796.0.
On 07th October 2019, AZNâs share price recorded at GBX 8,227.88 was its 52-week peak price, whereas, on 28th January 2019, the share price recorded at GBX 5,312.0 was the 52-week low share price. The current share price was lower by 4.75 per cent from the 52-week high price, whereas it was higher by 47.53 per cent from the 52-week low price. The companyâs market capitalisation was reported at £103.91 billion at the time of writing.
While writing, the beta of the AZN share was at 0.77, which shows low volatility as compared to the benchmark market indexâs movement.
GlaxoSmithKline Plc
GlaxoSmithKline Plc (LON:GSK) is an international healthcare company. The company has three business divisions, that are development, research and production of consumer healthcare products, advanced pharmaceutical medicines and vaccines.
GSK â Share Price Performance
The share price of AZN on 20th January 2020 (as at 16:35 GMT), closed at GBX 1,838.0 on the LSE (London Stock Exchange), declining by 0.43 per cent or GBX 8.0 per share, against the previous dayâs closing price of GBX 1,846.0.
GSKâs share price of GBX 1,851.15 as on 17th January 2020 was its 52-week peak price, whereas the share price of GBX 1,429.80 as on 28th January 2019 was its 52-week low share price. The current share price was lower by 0.71 per cent from the 52-week high price, whereas it was higher by 28.54 per cent from the 52-week low price.
The companyâs market capitalisation was reported at £92.11 billion at the time of writing. The free float and share outstanding of the GSK were reported at 4.94 million and 4.99 million, respectively.
While writing, the beta of the GSK share was at 0.87, which shows low volatility as compared to the benchmark market indexâs movement.
Smith & Nephew Plc (LON: SN.)
Smith & Nephew Plc (LON: SN.) with operations in over hundred countries across the globe, is a portfolio medical technology company. The companyâs shares are listed on the London Stock Exchange as well as on the New York Stock Exchange through American Depository Receipts.
Smith & Nephew Plc (LON: SN.) Share Price Performance
On 20th January 2020 as at 16:35 GMT, the share price of SN. closed at GBX 1,889.50 on the London Stock Exchange, a downside of 0.13 per cent or GBX 2.50 per share, versus previous dayâs closing price of GBX 1,887.0 per share.
SN.âs share price of GBX 1,998.40 as on 03rd September 2019 was its 52-week peak price, whereas the share price of GBX 1,402.0 as on 28th January 2019 was its 52-week low share price. The current share price was lower by 5.44 per cent from the 52-week high price, whereas it was higher by 34.77 per cent from the 52-week low price.
The companyâs market capitalisation was reported at £16.64 billion at the time of writing. The free float and share outstanding of the SN. were reported at 872.28 million and 875.07 million, respectively.
While writing, the beta of the SN. share was at 0.42, which shows very low volatility as compared to the benchmark market indexâs movement.Â
Hikma Pharmaceuticals Plc (LON:HIK)
Hikma Pharmaceuticals Plc (LON:HIK) is a pharmaceutical company. Itâs business is centred on production, development and marketing of a variety of both branded and non-branded in-licensed and generic products. The company's product segments include Injectables, Branded, Generics and Others.
HIK (LON:HIK) â Share Price Performance
At the time of writing, on 20th January 2020 as at 16:35 GMT, the share price of HIK closed at GBX 1,954.0 per share on the London Stock Exchange, a downside of 0.08 per cent or GBX 1.50 per share, versus previous dayâs closing price of GBX 1,955.50 per share.
HIKâs share price of GBX 2,212.0 as on 30th September 2019 was its 52-week peak price, whereas the share price of GBX 1,491.50 as on 29th January 2019 was its 52-week low share price. The current share price was lower by 11.66 per cent from the 52-week high price, whereas it was higher by 31.0 per cent from the 52-week low price.
The companyâs market capitalisation was reported at £4.76 billion at the time of writing. The free float and share outstanding of the HIK were reported at 133.71 million and 242.32 million, respectively.
While writing, the beta of the HIK share was at 0.79, which shows low volatility as compared to the benchmark market indexâs movement.
